Savara Announces Pricing of $130.0 Million Public Offering of Common Stock and Pre-funded Warrants
Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the pricing of an underwritten public offering of 23,809,524 shares of its common stock at a price of $4.20 per share and, in lieu of common stock to certain investors that so choose, pre-funded warrants to purchase 7,142,857 shares of common stock at a price of $4.199 per pre-funded warrant, in each case, before deducting underwriting discounts and commissions, for total gross proceeds of $130.0 million. All of the securities to be sold in the offering are being sold by Savara. Savara also granted the underwriters a 30-day option to purchase up to an additional 4,642,857 shares of common stock at the public offering price, less underwriting discounts and commissions. The offering is expected to close on October 31, 2025, subject to the satisfaction of customary closing conditions.
Savara Announces Proposed Public Offering
Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that it has commenced an underwritten public offering of shares of its common stock and, in lieu of common stock to certain investors, pre-funded warrants to purchase shares of its common stock. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the proposed offering may be completed, or as to the actual size or terms of the proposed offering. Savara intends to use the proceeds of the offering for general corporate purposes, which include the funding of clinical development of and pursuing regulatory approval for MOLBREEVI*, investing in commercialization infrastructure and supply, commercial launch preparation activities in the United States and European Union, and general and administrative expenses. In addition, Savara intends to grant the underwriters of the proposed offering a 30-day option to purchase up to an additional 15% of the number of shares of common stock and pre-funded warrants offered.
Savara announces $75M Royalty Funding Agreement with RTW to Support the Potential Launch of MOLBREEVI* in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP)
Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, announced a $75 million royalty funding agreement with funds managed by RTW Investments, LP (RTW), subject to FDA approval of MOLBREEVI.
Investors in Savara Inc. Should Contact Levi & Korsinsky Before November 7, 2025 to Discuss Your Rights - SVRASearch for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Investors in Savara Inc. Should Contact Levi & Korsinsky Before November 7, 2025 to Discuss Your Rights - SVRANEW YORK - October 29, 2025 ( NEWMEDIAWIRE ) - Levi & Korsinsky, LLP notifies investors in Savara Inc. (
NASDAQ: SVRA) of a class action securities lawsuit.
Savara Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before November 7, 2025 to Discuss Your Rights - SVRASearch for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Savara Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before November 7, 2025 to Discuss Your Rights - SVRANEW YORK - October 28, 2025 ( NEWMEDIAWIRE ) - Levi & Korsinsky, LLP notifies investors in Savara Inc. (
NASDAQ: SVRA) of a class action securities lawsuit.
SAVARA DEADLINE ALERT: Bragar Eagel & Squire, P.C. Urgently Reminds Savara Stockholders of the November 7th Deadline in the Filed Class Action LawsuitBragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Savara (SVRA) To Contact Him Directly To Discuss Their Options
SVRA Investors Have Opportunity to Lead Savara Inc. Securities Fraud Lawsuit with the Schall Law FirmLOS ANGELES, Oct. 27, 2025 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Savara Inc. (“Savara” or “the Company”) (
NASDAQ: SVRA) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
SVRA SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of SavaraFaruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Savara To Contact Him Directly To Discuss Their Options
Class Action Filed Against Savara Inc. (SVRA) Seeking Recovery for Investors - Contact Levi & KorsinskyNEW YORK - October 24, 2025 ( NEWMEDIAWIRE ) - Levi & Korsinsky, LLP notifies investors in Savara Inc. (
NASDAQ: SVRA) of a class action securities lawsuit.
Class Action Filed Against Savara Inc. (SVRA) Seeking Recovery for Investors - Contact Levi & KorsinskySearch for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Pomerantz Law Firm Announces the Filing of a Class Action Against Savara Inc. and Certain Officers – SVRANEW YORK, Oct. 24, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Savara Inc. (“Savara” or the “Company”) (
NASDAQ: SVRA) and certain officers. The class action, filed in the United States District Court for the Eastern District of Pennsylvania, and docketed under 25-cv-05147, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Savara securities between March 7, 2024 and May 23, 2025, both dates inclusive (the “Class Period”), seeking to recover damages caused by Defendants’ violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder, against the Company and certain of its top officials.
SAVARA CLASS ACTION ALERT: Bragar Eagel & Squire, P.C. Urgently Reminds Investors of the November 7th Deadline in the Filed Class Action LawsuitBragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Savara (SVRA) To Contact Him Directly To Discuss Their Options
Shareholders That Lost Money on Savara Inc. (SVRA) Urged to Join Class Action - Contact Levi & Korsinsky to Learn MoreSearch for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Shareholders That Lost Money on Savara Inc. (SVRA) Urged to Join Class Action - Contact Levi & Korsinsky to Learn MoreNEW YORK - October 23, 2025 ( NEWMEDIAWIRE ) - Levi & Korsinsky, LLP notifies investors in Savara Inc. (
NASDAQ: SVRA) of a class action securities lawsuit.
SVRA Investors Have Opportunity to Lead Savara Inc. Securities Fraud Lawsuit with the Schall Law FirmLOS ANGELES, Oct. 22, 2025 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Savara Inc. (“Savara” or “the Company”) (
NASDAQ: SVRA) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Savara Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before November 7, 2025 to Discuss Your Rights - SVRASearch for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Savara Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before November 7, 2025 to Discuss Your Rights - SVRANEW YORK - October 22, 2025 ( NEWMEDIAWIRE ) - Levi & Korsinsky, LLP notifies investors in Savara Inc. (
NASDAQ: SVRA) of a class action securities lawsuit.
Contact Levi & Korsinsky by November 7, 2025 Deadline to Join Class Action Against Savara Inc. (SVRA)Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Contact Levi & Korsinsky by November 7, 2025 Deadline to Join Class Action Against Savara Inc. (SVRA)NEW YORK - October 21, 2025 ( NEWMEDIAWIRE ) - Levi & Korsinsky, LLP notifies investors in Savara Inc. (
NASDAQ: SVRA) of a class action securities lawsuit.
Pomerantz Law Firm Announces the Filing of a Class Action Against Savara Inc. and Certain Officers – SVRANEW YORK, Oct. 20, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Savara Inc. (“Savara” or the “Company”) (
NASDAQ: SVRA) and certain officers. The class action, filed in the United States District Court for the Eastern District of Pennsylvania, and docketed under 25-cv-05147, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Savara securities between March 7, 2024 and May 23, 2025, both dates inclusive (the “Class Period”), seeking to recover damages caused by Defendants’ violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder, against the Company and certain of its top officials.
Class Action Filed Against Savara Inc. (SVRA) - November 7, 2025 Deadline to Join - Contact Levi & KorsinskySearch for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Class Action Filed Against Savara Inc. (SVRA) - November 7, 2025 Deadline to Join - Contact Levi & KorsinskyNEW YORK - October 20, 2025 ( NEWMEDIAWIRE ) - Levi & Korsinsky, LLP notifies investors in Savara Inc. (
NASDAQ: SVRA) of a class action securities lawsuit.
SAVARA CLASS ACTION REMINDER: Bragar Eagel & Squire, P.C. Urges Savara, Inc. Investors to Contact the Firm Before November 7th DeadlineBragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Savara (SVRA) To Contact Him Directly To Discuss Their Options
